|
1
|
Wiese M, Schill F, Sturm D, Pfister S,
Hulleman E, Johnsen SA and Kramm CM: No significant cytotoxic
effect of the EZH2 inhibitor tazemetostat (EPZ-6438) on pediatric
glioma cells with wildtype histone 3 or mutated histone 3.3. Klin
Padiatr. 228:113–117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jones C, Perryman L and Hargrave D:
Paediatric and adult malignant glioma: close relatives or distant
cousins? Nat Rev Clin Oncol. 9:400–413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jones DT, Gronych J, Lichter P, Witt O and
Pfister SM: MAPK pathway activation in pilocytic astrocytoma. Cell
Mol Life Sci. 69:1799–1811. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hargrave D: Paediatric high and low grade
glioma: the impact of tumour biology on current and future therapy.
Br J Neurosurg. 23:351–363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khatua S, Moore KR, Vats TS and Kestle JR:
Diffuse intrinsic pontine glioma-current status and future
strategies. Childs Nerv Syst. 27:1391–1397. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pollack IF, Stewart CF, Kocak M, Poussaint
TY, Broniscer A, Banerjee A, Douglas JG, Kun LE, Boyett JM and
Geyer JR: A phase II study of gefitinib and irradiation in children
with newly diagnosed brainstem gliomas: a report from the Pediatric
Brain Tumor Consortium. Neuro Oncol. 13:290–297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mueller S and Chang S: Pediatric brain
tumors: current treatment strategies and future therapeutic
approaches. Neurotherapeutics. 6:570–586. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hardesty DA and Sanai N: The value of
glioma extent of resection in the modern neurosurgical era. Front
Neurol. 3:1402012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moghrabi A, Friedman HS, Burger PC, Tien R
and Oakes WJ: Carboplatin treatment of progressive optic pathway
gliomas to delay radiotherapy. J Neurosurg. 79:223–227. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Urbański B: The future of radiation
oncology: considerations of young medical doctor. Rep Pract Oncol
Radiother. 17:288–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kortmann RD, Jeremic B and Bamberg M:
Radiotherapy in the management of low-grade gliomasCombined
Modality Therapy for Central Nervous System Tumors. Petrowich Z,
Brady LW, Apuzzo ML and Bamberg M: Springer; Berlin: pp. 317–326.
2000
|
|
12
|
Kortmann RD, Timmermann B, Taylor RE,
Scarzello G, Plasswilm L, Paulsen F, Jeremic B, Gnekow AK,
Dieckmann K, Kay S, et al: Current and future strategies in
radiotherapy of childhood low-grade glioma of the brain. Part I:
treatment modalities of radiation therapy. Strahlenther Onkol.
179:509–520. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Burzynski SR: Treatments for astrocytic
tumors in children: current and emerging strategies. Paediatr
Drugs. 8:167–178. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Preusser M, Haberler C and Hainfellner JA:
Malignant glioma: neuropathology and neurobiology. Wien Med
Wochenschr. 156:332–337. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cruet-Hennequart S, Glynn MT, Murillo LS,
Coyne S and Carty MP: Enhanced DNA-PK-mediated RPA2
hyperphosphorylation in DNA polymerase eta-deficient human cells
treated with cisplatin and oxaliplatin. DNA Repair (Amst).
7:582–596. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mutter N and Stupp R: Temozolomide: a
milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther.
6:1187–1204. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gállego Pérez-Larraya J, Ducray F, Chinot
O, Catry-Thomas I, Taillandier L, Guillamo JS, Campello C, Monjour
A, Cartalat-Carel S, Barrie M, et al: Temozolomide in elderly
patients with newly diagnosed glioblastoma and poor performance
status: An ANOCEF phase II trial. J Clin Oncol. 29:3050–3055. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Welzel G, Gehweiler J, Brehmer S, Appelt
JU, von Deimling A, Seiz-Rosenhagen M, Schmiedek P, Wenz F and
Giordano FA: Metronomic chemotherapy with daily low-dose
temozolomide and celecoxib in elderly patients with newly diagnosed
glioblastoma multiforme: A retrospective analysis. J Neurooncol.
124:265–273. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cohen MH, Johnson JR and Pazdur R: Food
and Drug Administration Drug approval summary: temozolomide plus
radiation therapy for the treatment of newly diagnosed glioblastoma
multiforme. Clin Cancer Res. 11:6767–6771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups; National Cancer
Institute of Canada Clinical Trials Group: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hegi ME, Liu L, Herman JG, Stupp R, Wick
W, Weller M, Mehta MP and Gilbert MR: Correlation of
O6-methylguanine methyltransferase (MGMT) promoter
methylation with clinical outcomes in glioblastoma and clinical
strategies to modulate MGMT activity. J Clin Oncol. 26:4189–4199.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jalali R, Raut N, Arora B, Gupta T, Dutta
D, Munshi A, Sarin R and Kurkure P: Prospective evaluation of
radiotherapy with concurrent and adjuvant temozolomide in children
with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat
Oncol Biol Phys. 77:113–118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kuo DJ, Weiner HL, Wisoff J, Miller DC,
Knopp EA and Finlay JL: Temozolomide is active in childhood,
progressive, unresectable, low-grade gliomas. J Pediatr Hematol
Oncol. 25:372–378. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lashford LS, Thiesse P, Jouvet A, Jaspan
T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R,
et al: United Kingdom Children's Cancer Study Group and French
Society for Pediatric Oncology Intergroup Study: Temozolomide in
malignant gliomas of childhood: a United Kingdom Children's Cancer
Study Group and French Society for Pediatric Oncology Intergroup
Study. J Clin Oncol. 20:4684–4691. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jakacki RI, Yates A, Blaney SM, Zhou T,
Timmerman R, Ingle AM, Flom L, Prados MD, Adamson PC and Pollack
IF: A phase I trial of temozolomide and lomustine in newly
diagnosed high-grade gliomas of childhood. Neuro Oncol. 10:569–576.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gaspar N, Marshall L, Perryman L, Bax DA,
Little SE, Viana-Pereira M, Sharp SY, Vassal G, Pearson AD, Reis
RM, et al: MGMT-independent temozolomide resistance in pediatric
glioblastoma cells associated with a PI3-kinase-mediated
HOX/stem cell gene signature. Cancer Res. 70:9243–9252.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fassan M, Tassone E, Onisto M, Perilongo
G, D'Avella D and Gardiman MP: MGMT promoter methylation in
pediatric high-grade gliomas. Childs Nerv Syst. 27:7–8. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Perilongo G: Considerations on the role of
chemotherapy and modern radiotherapy in the treatment of childhood
low grade glioma. J Neurooncol. 75:301–307. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ater JL, Zhou T, Holmes E, Mazewski CM,
Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, et
al: Randomized study of two chemotherapy regimens for treatment of
low-grade glioma in young children: a report from the Children's
Oncology Group. J Clin Oncol. 30:2641–2647. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Massimino M, Spreafico F, Cefalo G,
Riccardi R, Tesoro-Tess JD, Gandola L, Riva D, Ruggiero A,
Valentini L, Mazza E, et al: High response rate to
cisplatin/etoposide regimen in childhood low-grade glioma. J Clin
Oncol. 20:4209–4216. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Miller RP, Tadagavadi RK, Ramesh G and
Reeves WB: Mechanisms of cisplatin nephrotoxicity. Toxins (Basel).
2:2490–2518. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Genc DB, Canpolat C and Berrak SG:
Clinical features and management of carboplatin-related
hypersensitivity reactions in pediatric low-grade glioma. Support
Care Cancer. 20:385–393. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kann HE Jr, Kohn KW, Widerlite L and
Gullion D: Effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and
related compounds on nuclear RNA metabolism. Cancer Res.
34:1982–1988. 1974.PubMed/NCBI
|
|
34
|
Geyer JR, Finlay JL, Boyett JM, Wisoff J,
Yates A, Mao L and Packer RJ: Survival of infants with malignant
astrocytomas. A report from the Childrens Cancer Group. Cancer.
75:1045–1050. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chastagner P, Kalifa C, Doz F, Bouffet E,
Gentet JC, Ruchoux MM, Bracard S, Desandes E and Frappaz D: French
Society of Pediatric Oncology (SFOP) Pilot Study: Outcome of
children treated with preradiation chemotherapy for a high-grade
glioma: results of a French Society of Pediatric Oncology (SFOP)
Pilot Study. Pediatr Blood Cancer. 49:803–807. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vos SM, Tretter EM, Schmidt BH and Berger
JM: All tangled up: how cells direct, manage and exploit
topoisomerase function. Nat Rev Mol Cell Biol. 12:827–841. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Salerno S, Da Settimo F, Taliani S,
Simorini F, La Motta C, Fornaciari G and Marini AM: Recent advances
in the development of dual topoisomerase I and II inhibitors as
anticancer drugs. Curr Med Chem. 17:4270–4290. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Moukharskaya J and Verschraegen C:
Topoisomerase 1 inhibitors and cancer therapy. Hematol Oncol Clin
North Am. 26:507–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bax DA, Gaspar N, Little SE, Marshall L,
Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY,
Reis-Filho JS, et al: EGFRvIII deletion mutations in pediatric
high-grade glioma and response to targeted therapy in pediatric
glioma cell lines. Clin Cancer Res. 15:5753–5761. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Geoerger B, Hargrave D, Thomas F, Ndiaye
A, Frappaz D, Andreiuolo F, Varlet P, Aerts I, Riccardi R, Jaspan
T, et al: ITCC (Innovative Therapies for Children with Cancer)
European Consortium: Innovative therapies for children with cancer
pediatric phase I study of erlotinib in brainstem glioma and
relapsing/refractory brain tumors. Neuro Oncol. 13:109–118. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yalon M, Rood B, MacDonald TJ, McCowage G,
Kane R, Constantini S and Packer RJ: A feasibility and efficacy
study of rapamycin and erlotinib for recurrent pediatric low-grade
glioma (LGG). Pediatr Blood Cancer. 60:71–76. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Paugh BS, Broniscer A, Qu C, Miller CP,
Zhang J, Tatevossian RG, Olson JM, Geyer JR, Chi SN, da Silva NS,
et al: Genome-wide analyses identify recurrent amplifications of
receptor tyrosine kinases and cell-cycle regulatory genes in
diffuse intrinsic pontine glioma. J Clin Oncol. 29:3999–4006. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hillen F and Griffioen AW: Tumour
vascularization: sprouting angiogenesis and beyond. Cancer
Metastasis Rev. 26:489–502. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cohen MH, Shen YL, Keegan P and Pazdur R:
FDA drug approval summary: bevacizumab (Avastin) as treatment of
recurrent glioblastoma multiforme. Oncologist. 14:1131–1138. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu AK, Macy ME and Foreman NK:
Bevacizumab as therapy for radiation necrosis in four children with
pontine gliomas. Int J Radiat Oncol Biol Phys. 75:1148–1154. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Javier RT and Butel JS: The history of
tumor virology. Cancer Res. 68:7693–7706. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Matlaf LA, Harkins LE, Bezrookove V, Cobbs
CS and Soroceanu L: Cytomegalovirus pp71 protein is expressed in
human glioblastoma and promotes pro-angiogenic signaling by
activation of stem cell factor. PLoS One. 8:e681762013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Penkert RR and Kalejta RF: Tale of a
tegument transactivator: the past, present and future of human CMV
pp71. Future Virol. 7:855–869. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rahbar A, Stragliotto G, Orrego A, Peredo
I, Taher C, Willems J and Söderberg-Naucler C: Low levels of human
cytomegalovirus infection in glioblastoma multiforme associates
with patient survival; - a case-control study. Herpesviridae.
3:32012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Crough T, Beagley L, Smith C, Jones L,
Walker DG and Khanna R: Ex vivo functional analysis, expansion and
adoptive transfer of cytomegalovirus-specific T-cells in patients
with glioblastoma multiforme. Immunol Cell Biol. 90:872–880. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Prins RM, Cloughesy TF and Liau LM:
Cytomegalovirus immunity after vaccination with autologous
glioblastoma lysate. N Engl J Med. 359:539–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
